Tag Archives: AbbVie Inc.

Top Stories for Week of July 13, 2020

Fierce US surge adds over one million new coronavirus cases the past four weeks, ending months of declining national death totals. Since the first US case of the new coronavirus… Read more »

In a seeming role-reversal, FDA steps up action over Thanksgiving week while EMA goes on holiday.

Although usually thought of as a well-deserved respite from governmental rulings, the US Food and Drug Administration seized on Thanksgiving week as a demonstration of its zeal to pump out… Read more »

Voyager Therapeutics signs another neurodegenerative disease deal with AbbVie that screams “Buy this small cap now.”

The News: Voyager Therapeutics Inc. (Cambridge MA) struck a deal with AbbVie Inc. (North Chicago) to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s… Read more »

Why Galapagos’s Phase 3 rheumatoid arthritis success is largely irrelevant.

The News: Galapagos NV (Mechelen BEL) and Gilead Sciences Inc. (Foster City CA) have reported positive results from a Phase 3 trial testing Galapagos’s lead drug candidate in patients with… Read more »

Tiny Swedish biotech not taking back seat to US in Alzheimer’s race. How to buy it.

The News: BioArctic AB, based in Stockholm, said it has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial… Read more »

Wondering why some of your Pharma shares keep going up? Thank Trump’s tax “reform;” no, really.

The News: The drug industry has taken heat from patient advocates and a US senator for handing out its tax savings to shareholders instead of using its windfall to help patients… Read more »

Patients lose, lawyers win, as AbbVie does deal with Amgen to delay Humira biosim.

The News: Amgen Inc. (Thousand Oaks CA) has agreed to delay the US launch of its FDA-approved biosimilar version of AbbVie Inc.’s (North Chicago) Humira (adalimumab) until 2023, under a… Read more »

Amgen, Allergan get nod for Avastin biosim; FDA’s Gottlieb making good on vow to hasten generic approvals, catch the EU.

The News: Amgen Inc. (Thousand Oaks CA) and Allergan PLC (Dublin IRL) said Thursday (September 14, 2017) that the Food and Drug Administration has approved their biosimilar version of Roche… Read more »

Alexion on a roll as Soliris gets label expansion in EU; although flying under the radar, analysts, investors still bullish.

The News: Alexion Pharmaceuticals Inc. (New Haven CT) got another shot in the arm this week with the EU approving its key revenue driver Soliris for an additional indication. EU approval… Read more »